drugset / Trial / NCT07714447
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study investigated the efficacy and safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer.
Timeline
- Start
- 2026-11-30
- Primary completion
- 2029-02-01
- Completion
- 2029-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab β | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Dabrafenib | Small molecule | — | — |
| Subject | Encorafenib | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Vemurafenib | Small molecule | — | — |
| Background | Tunlametinib | Small molecule | 9 mg | Oral |